Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

Hartford HealthCare in partnership with Quinnipiac

Hartford HealthCare and Quinnipiac University report a new partnership to bolster training of the healthcare workforce with new programs and funding. HHC will spend $5 million over the...

| By Caitlin Truesdale

Artizan picks lead candidate against bowel disease

Artizan Biosciences reports that it has selected its lead product candidate,  ARZC-001, for the treatment of inflammatory bowel disease. The New Haven-based biotechnology company describes the candidate...

| By Caitlin Truesdale

Weekly Roundup – January 27, 2022

See the full Roundup in your browser here. CytoVeris is leveraging the convergence of powerful optical technologies, the biology of carcinogenesis, and artificial intelligence to bring...

| By Caitlin Truesdale

Smithsonian names Yale “detergent” top discovery

Work from the laboratory of John MacMicking in the Yale Systems Biology Institute was recently named one of 10 innovative discoveries for 2021, according to the Smithsonian...

| By Caitlin Truesdale

MannKInd now names Danbury its corporate home

MannKind is now designating Danbury as principal executive office in filings with the U.S. Securities and Exchange Commission, with the company having long operated an insulin...

| By Caitlin Truesdale

Career Newsletter

To read the full email in your browser click here. University of New Haven Virtual STEM Career Fair February 24, 2022 1:00 pm – 4:00...

| By Caitlin Truesdale

CaroGen Hepatitis B vaccine gets Federal funding

Farmington-based bioscience startup CaroGen reports its immunotherapy vaccine that targets chronic Hepatitis B has been recommended for $6.8 million in federal funding by the U.S. Department of Defense....

| By Caitlin Truesdale

Sema4 plans to buy Maryland testing firm GeneDX

Stamford’s Sema4 plans to buy genomic testing firm GeneDx of Maryland in a deal that projects $350 million in revenue for the combined companies this year. GeneDx...

| By Caitlin Truesdale

Cybrexa sees potential in tumor targeting peptides

Despite all of the advances made in treating different cancers over the past several years, there is still significant room for improvement in oncology. That’s...

| By Caitlin Truesdale

Weekly Roundup – January 20, 2022

See the full Roundup here. What do you know about stock-based compensation? It’s good to get an expert opinion on the subject! Marcum‘s Katie Daiell...